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Non-tuberculous Mycobacteria 
isolated from Pulmonary samples in 
sub-Saharan Africa - A Systematic 
Review and Meta Analyses
Catherine Okoi1, Suzanne T.B Anderson2, Martin Antonio1,3,4, Sarah N. Mulwa5,  
Florian Gehre1,6 & Ifedayo M.O. Adetifa  7,8,9
Pulmonary non-tuberculous mycobacterial (NTM) disease epidemiology in sub-Saharan Africa is not 
as well described as for pulmonary tuberculosis. Earlier reviews of global NTM epidemiology only 
included subject-level data from one sub-Saharan Africa country. We systematically reviewed the 
literature and searched PubMed, Embase, Popline, OVID and Africa Wide Information for articles on 
prevalence and clinical relevance of NTM detection in pulmonary samples in sub-Saharan Africa. We 
applied the American Thoracic Society/Infectious Disease Society of America criteria to differentiate 
between colonisation and disease. Only 37 articles from 373 citations met our inclusion criteria. The 
prevalence of pulmonary NTM colonization was 7.5% (95% CI: 7.2%–7.8%), and 75.0% (2325 of 3096) 
occurred in males, 16.5% (512 of 3096) in those previously treated for tuberculosis and Mycobacterium 
avium complex predominated (27.7% [95% CI: 27.2–28.9%]). In seven eligible studies, 27.9% (266 of 
952) of participants had pulmonary NTM disease and M. kansasii with a prevalence of 69.2% [95% CI: 
63.2–74.7%] was the most common cause of pulmonary NTM disease. NTM species were unidentifiable 
in 29.2% [2,623 of 8,980] of isolates. In conclusion, pulmonary NTM disease is a neglected and emerging 
public health disease and enhanced surveillance is required.
The epidemiology of pulmonary disease caused by Mycobacterium tuberculosis complex (MTBC) - M. tuberculo-
sis, M. bovis, M. africanum, M. canetti, M. microti, M. pinnipedii and M. caprae - is better known than for NTM1. 
NTM is a designation used for a large number of potentially pathogenic and non-pathogenic environmental 
mycobacterial species other than MTBC and Mycobacterium leprae.
Worldwide, pulmonary infections caused by NTM are gaining increased attention, in part, because of their 
increasing recognition and isolation in clinical settings, for example with better known NTM pathogens such as 
M. avium subsp paratuberculosis, M. marinum, etc.2,3. Although NTM were identified soon after Koch’s identifi-
cation of M. tuberculosis as the cause of active tuberculosis in 1882, it was not until the 1950s that NTM were rec-
ognized to cause human pulmonary disease. Given their ubiquitous presence in the environment, it is important 
to distinguish colonization from active disease following isolation of NTM from pulmonary samples. In response 
to this challenge, the ATS/IDSA introduced stringent diagnostic criteria with clinical, radiological and microbio-
logical components for diagnosis of pulmonary NTM disease2.
The clinical and molecular epidemiology of prevalent NTM in low and middle-income countries, also 
endemic for pulmonary tuberculosis, is less known because pulmonary and other disease manifestations caused 
by NTM pose a diagnostic challenge to microbiologists and clinicians2,4. In contrast to pulmonary tuberculosis, it 
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is not possible to readily identify pulmonary NTM disease with the usual combination of basic mycobacteriology, 
clinical history, radiologic imaging and the tuberculin skin test, where applicable. The culture and molecular 
biology identification techniques required for NTM diagnosis are not cost effective for routine clinical practice in 
resource-poor health systems where priority is currently given to expanding access to diagnosis and treatment for 
pulmonary tuberculosis5,6. The distribution of NTM species isolated from pulmonary samples differs significantly 
by geographic region. However, most of these data are from the developed world and sub-Saharan Africa is under 
represented7,8. Although there are now emerging NTM disease data from Asia and parts of Africa, significant 
knowledge gaps still exist especially in sub-Saharan Africa where nine of the world’s 22 high burden tuberculosis 
countries are found8–11. Therefore, fears that inconclusive diagnosis based on smear microscopy or clinical symp-
toms and/or radiological findings could lead to misdiagnosis of pulmonary tuberculosis and/or inappropriate 
management of pulmonary NTM cases are valid. As it is especially to difficult to differentiate between NTM col-
onisation and NTM disease the American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) 
defined a set of clinical and microbiological criteria to diagnose pulmonary NTM disease (Table 1).
The objectives of this review are to consolidate existing data on NTM colonisation and disease (according to 
ATS/ISDA criteria) in sub-Saharan Africa, review the existing gaps in our knowledge of pulmonary NTM and 
identify future research priorities.
Methods
Literature Search and Selection Criteria. This review was conducted in accordance with PRISMA guide-
lines12. The overall aim of this review was to determine the prevalence of NTM in apparently healthy and diseased 
individuals in sub-Saharan Africa. We defined sub-Saharan Africa as all of Africa except Northern Africa.
Search strategy. We searched PubMed, EMBASE, POPLINE, OVID and Africa Wide Information elec-
tronic databases for publications about pulmonary NTM in sub-Saharan Africa published from January 1, 1940 
to October 1, 2016 using the following search terms and strategy: ((((((“nontuberculous mycobacteria”[MeSH 
Terms] AND “africa south of the sahara”[MeSH Terms]) OR “mycobacterium infections, nontuberculous”[MeSH 
Terms]) AND “africa south of the sahara”[MeSH Terms]) OR “mycobacterium infections, nontubercu-
lous”[MeSH Terms]) AND “africa south of the sahara”[MeSH Terms]) OR ((“lung”[MeSH Terms] OR “lung”[All 
Fields] OR “pulmonary”[All Fields]) AND “nontuberculous mycobacteria”[MeSH Terms])) AND “africa south of 
the sahara”[MeSH Terms] AND ((“1940/01/01”[PDAT]: “2016/10/01”[PDAT]) AND “humans”[MeSH Terms]).
Selection process and data abstraction. We found 373 citations from our database searches (see Fig. 1). 
The titles and abstracts of all the articles were screened and full-text copies of those deemed relevant obtained. 
In addition, the reference sections of all the retrieved articles were screened to identify other eligible citations. 
Only articles reporting on pulmonary samples were included. For all relevant articles, we extracted the following 
data using a data extraction sheet: research setting, study period, population tested and numbers, NTM species 
isolated, method for NTM identification, prevalence of pulmonary NTM isolation/disease, HIV co- infection rate 
and risk factor(s) for NTM acquisition.
Data analysis. In estimating country-level and overall prevalence of NTM in sub-Saharan Africa, a pooled 
estimate was computed based on a simple meta-analysis of the reported prevalences. Each study was weighted 
according to its sample size and the exact binomial used to derive the 95% confidence intervals (95% CI). We 
checked all retrieved articles for application of the ATS/IDSA diagnostic criteria (Table 1) for clinically relevant 
pulmonary NTM and recorded the proportion of patients meeting these criteria and NTM species responsible.
Clinical
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed 
tomographic scan that shows multifocal bronchiectasis with multiple small nodules.
And
2. Appropriate exclusion of other diagnoses.
Microbiologic
1. Positive culture results from at least two separate expectorated sputum samples (If the results from the initial 
sputum samples are non-diagnostic, consider repeat sputum acid-fast bacillus (AFB) smears and cultures).
OR
2. Positive culture results from at least one bronchial wash or lavage.
OR
3. Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation 
or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features (granulomatous 
inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that 
usually represent environmental contamination.
5. Patients who are suspected of having NTM lung disease but who do not meet the diagnostic criteria should be 
followed until the diagnosis is firmly established or excluded.
Table 1. Summary of the American Thoracic Society/Infectious Disease Society of America diagnostic criteria 
for pulmonary non-tuberculous mycobacterial infection/disease2.
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All extracted data were stored in Microsoft® Excel® (Microsoft Corporation, Redmond, Washington, United 
States) and analysis carried out in STATA™ version 12.1 (College Station, Texas, United States).
Results
Description of included studies. There were only 37 relevant articles on the epidemiology of pulmonary 
NTM in sub-Saharan Africa as shown in Table 2. These were from studies in western (Nigeria, Mali and Ghana), 
southern (Zambia and South Africa [RSA]) and eastern (Kenya, Uganda, Tanzania and Ethiopia) Africa5,6,8,10,13–44. 
Eleven articles were from Nigeria5,13,15–21,45,46, one from Mali22, one from Ghana23, six from Zambia6,10,24–27, two 
from Kenya28,29, two from Uganda30,31, three from Tanzania32–34, three from Ethiopia35–37 and eight from South 
Africa8,38–40,43,44.
Where methods of identification were reported, molecular techniques (n = 26) were the most frequently used 
to identify NTM species, followed by conventional biochemical testing identification tools (n = 9) and immuno-
chromatographic assays (n = 2). The molecular diagnostic methods used were Restriction Fragment Polymerase 
Chain Reaction (RFPCR) of the 65KD hsp gene, Genotype CM/AS assay (Hain Life science, Nehren, Germany), 
and 16S rRNA gene sequencing analysis in one, eleven and fourteen studies respectively. Identification methods 
also varied over time and a dramatic rise in the use of molecular methods was observed in the period 2000-2016. 
Biochemical and phenotypic tools were the only methods used for NTM identification before 2000. Despite this 
transition in identification methods used over time, there was no major change in diversity of NTM species iso-
lated in the period before and after the year 2000 as shown in Table 3.
Synthesis of Results
Epidemiology of Non-tuberculous Mycobacteria. The overall prevalence of NTM in pulmonary sam-
ples in sub-Saharan Africa derived from all 37 papers reviewed was 7.5% (95% CI: 7.2–7.8%). The median age of 
participants was 35 (Interquartile range, IQR 16–80) years based on 17 of 37 studies with age data. The majority 
(2325 [75.0%] of 3096) of subjects with NTM were males. Patients in 12 of 37 studies (32.4%) had a previous 
history of pulmonary tuberculosis and 15 (40.5%) were co-infected with HIV.
MAC species accounted for 28.0% (95% CI: 27.2–28.9%) of all NTM isolated and was the most frequently 
encountered NTM found in pulmonary samples in 19 of 37 studies. The prevalence of MAC ranged from 15.0% 
(95% CI: 5.05–25.0%) in Tanzania to 57.8% (95% CI: 36.3–76.9%) in Mali as shown in Fig. 2 (along with country 
Figure 1. Flow chart of literature search and article selection criteria.
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Country Study period Reference
Age in 
years Sample size
Sputum cultures
Most isolated 
NTM
Method of NTM 
identification
Overall 
prevalence 
of NTM 
isolation (%)
Pulmonary 
NTM 
patients 
with HIV 
coinfection 
(%)
ATS/IDSA 
applied/
numbers 
meeting 
criteria
Risk 
factors for 
pulmonary 
NTMMTBC NTM
Ethiopia 2010 Mathewos et al.36 NA
263 presumptive 
TB cases 110 7 NTM not classified
Immunochro-matography 
assay (Capilia TAUNS 
method)
2.7 NA No NA
Ethiopia 2011 Workalemahu et al.37 1–15
121 presumptive 
TB cases 15 10
M. fortuitum M. 
parascrofulaceum 
M. triviale
Molecular (Sequencing of 
16S rRNA gene) 8.3 NA NA NA
Ethiopia 2008–09 Gumi et al.35 NA 260 presumptive TB cases 157 7 M. flavescens
Molecular (Sequencing of 
16S rRNA gene) 2.7 NA No NA
Ghana 2013–14 Bjerrum et al.23 ≥18
473 HIV infected 
adults 60 38
M. avium complex 
M. chelonae M. 
simiae M. fortuitum
Molecular (sequencing of 
16S rRNA gene) 8.0
All HIV 
infected No
HIV 
infection 
and age
Kenya 2007–09 Nyamogoba et al.28 ≥0
872 presumptive 
TB cases 346 15
M. fortuitum M. 
peregrinum
Molecular (Genotype 
CM/As assay) 1.7 46.7 No
Previous 
TB HIV 
infection
Kenya 2014–15 Limo et al.29 ≥0 210 retreatment cases 121 89
M. intracellulare 
M. abscessus M. 
fortuitum
Molecular (Genotype 
CM/As assay) 42.4 25.8 No
Previous TB 
infection
Mali 2004–09 Miaga et al.22 18–73 142 presumptive TB cases enrolled 113 17
M. avium M. 
palustre M. 
fortuitum
Molecular (sequencing of 
16S rRNA gene) 12.0 17.6 Yes; 11 Previous TB
Nigeria 2010–11 Olutayo  et al.13
319 presumptive 
TB cases 122 26 NA
Molecular (Genotype 
CM/AS assay) 8.2 46.2 No
HIV 
infection, 
age
Nigeria 2008–09 Cadmus  et al.46 NA
23 presumptive 
cases 11 9 M. avium complex
Molecular (Sequencing of 
16S rRNA gene) 39.1 NA No NA
Nigeria 2010–11 Gambo et al.15 NA 952 presumptive TB cases 254 65 NTM not classified
Molecular (Genotype 
CM/AS assay) 6.8 40.0 No
HIV 
infection, 
TB
Nigeria 2010–11 Gambo et al.5 18
1603 TB 
presumptive TB 
cases
375 69
M. intracellulare 
M. abscessus M. 
fortuitum M. 
gordonae
Molecular (Genotype 
CM/AS assay) 4.3 40.0 No
HIV 
infection, 
TB
Nigeria 2008–09 Asuquo  et al.16 10–70
137 presumptive 
TB cases 81 4
M. fortuitum M. 
avium species M. 
abscessus
Molecular (Genotype 
CM/AS assay) 2.9 50.0 No
HIV 
infection
Nigeria 1983 Idigbe et al.17 NA 668 presumptive TB cases NA NA
M. avium M. 
kansasii M. 
fortuitum
Conventional biochemical 
methods 11.0 NA NA NA
Nigeria 1982-93 Idigbe et al.18 NA NA NA NA
M. avium M. 
kansasii M. xenopi 
M. fortuitum
Conventional biochemical 
methods NA NA No NA
Nigeria NA Mawak et al.45 ≥14 329 presumptive cases 50 15
M. avium M. 
kansasii M. 
fortuitum
Conventional biochemical 
methods 4.6 NA No NA
Nigeria 2007–09 Daniel et al.19 25–80
102 TB patients 
(41 new s + and 
61 s + retreatment 
cases)
70 7
M. fortuitum M. 
intracellulare M. 
chelonae
Conventional biochemical 
methods 6.9 15.0 No Previous TB
Nigeria NA Allana et al.20 NA NA NA NA
M. avium M. 
kansasii M. 
fortuitum
Conventional biochemical 
methods NA NA NA NA
Nigeria 1963 Beer et al.21 ≥1 NA 2682 149 Runyon 111 and 1 V organisms
Conventional biochemical 
methods 6.0 NA No Previous TB
South Africa 2006–07 Clare et al.38 Median age–44
2496 presumptive 
TB cases 421 232
M. kansasii M. 
gordonae
Conventional biochemical 
methods 9.3 31.9 No
HIV 
infection
South Africa 1996–97 Corbett  et al.39 NA
TB presumptive 
cases NA 118
M. kansasii M. 
fortuitum M. 
scrofulaceum
Conventional biochemical 
methods NA 34.0 Yes; 32
Previous 
TB, silicosis
South Africa 1993–96 Corbett  et al.40 ≥18 594 mine workers NA
406 
NTM
M. kansasii M. 
fortuitum M. avium 
complex
Conventional biochemical 
methods 68.4 13.1 Yes; 206
HIV 
infection, 
silicosis
South Africa 1993–96 Corbett  et al.39 ≥18
243 NTM infected 
suspects 92 243
M. kansasii M. 
fortuitum M. 
intracellulare
Conventional biochemical 
methods 100 NA No
Previous 
TB, silicosis
South Africa 1993–96 Corbett  et al.40 ≥18 406 gold miners NA
261 
NTM 
patients
M. kansasii M. 
scrofulaceum
Conventional biochemical 
methods 64.3 NA No
Previous 
TB, HIV 
infection
South Africa 2001–05 Hartherill  et al.43
18 
(13–23) 
months
1732 presumptive 
TB cases 94 109
M. intracellulare M. 
gastri M. avium
Molecular (RFPCR of 65 
KD hspgene) 6.3 4.2 Yes; 8 Previous TB
South Africa 2009 Sookan et al.44 NA 200 NTM suspects NA
133 
NTM 
patients
M. avium complex. 
M. RGM M. 
gordonae
Molecular (Genotype 
CM/AS assay) 66.5 NA No NA
South Africa 2008 Hoefsloot et al.8 NA NA NA
5646 
NTM 
patients
MAC M. kansasii 
M. scrofulaceum M. 
gordonae
Molecular (Genotype 
CM/AS assay, AccuProbe 
assays, hsp 65 PCR–
restriction enzyme 
analysis, Inno–Lipa 
Mycobacteria and 
biochemical methods
NA NA NA NA
Continued
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HIV prevalence in the legend47). There was regional variability in the distribution of NTM for example; 76.4% 
(95% CI: 74.8–77.9%) i.e. 2,355 of 3,084 MAC isolates from South Africa were M. intracellulare, while all MAC 
isolates from Mali were M. avium. Similarly, while M. kansasii was the third most isolated NTM in sub-Saharan 
Africa overall (4.7% [95% CI: 4.3–5.1%]), it was the top NTM in five (62.5%) of eight studies in South Africa.
Other slow growing mycobacteria isolates, though less prevalent than MAC, were M. scrofulaceum 7.0% (95% 
CI: 6.4–7.5%) and M. gordonae 3.8% (95% CI: 3.4–4.3%). The rapidly growing mycobacteria i.e. M. fortuitum, 
M. chelonae, and M. abscessus accounted for just 1.2% (95% CI: 1.0–1.4%) of all NTM isolates from sub-Saharan 
Africa. Rapidly growing mycobacteria were reported predominantly from eastern African countries with M. 
fortuitum (43.0% [95% CI: 34.4–53.2%]) and M. abscessus (16.0% [95% CI: 9.4–25.9%]) as the top and second 
ranked NTM isolates from Uganda and Kenya respectively.
Among the 70.8% (6357 of 8980) fully speciated isolates in this review, there were 0.9% (56) M. lentiflavum, 
0.9% (55) M. malmoense, 0.7% (43) M. xenopi, 0.4% (24) M. gastri, 0.3% (16) M. szulgai, 0.2% (15) M. flavescens, 
and 0.2% (11) M. interjectum. Unfortunately, 29.2% (95% CI: 28.1–30.1%) i.e. 2,623 of all 8,980 NTM isolates 
were not identified to species level.
Epidemiology of Pulmonary Non-tuberculous Mycobacterial Disease. One particular challenge in 
studying NTM infection is the difficulty in differentiating between NTM colonisation of patients (due to the mere 
presence of the bacteria in the environment) and actual pulmonary disease. Therefore the American Thoracic 
Society/Infectious Disease Society of America (ATS/IDSA) defined a combination of stringent clinical and micro-
biological criteria to conclusively determine pulmonary disease (see Table 1). To evaluate the geographical distri-
bution of disease-causing NTM only, we excluded 30 articles that only reported on the detection of NTM without 
applying ATS/IDSA criteria and therefore could not show evidence of pulmonary disease. Only seven (19.0%) of 
the 37 articles were ATS/ISDA compliant and could be investigated in respect to the epidemiology of clinically 
relevant NTM6,22,26,34,39,40,43. Although these studies had 3,319 participants, only 962 (28.9%) had sufficient infor-
mation to apply the ATS/IDSA criteria and of these, 266 (27.7%) met the definition of pulmonary NTM disease. 
M. kansasii, isolated in 184 (69.2%) of 266 cases, was the most predominant cause of confirmed pulmonary NTM 
disease, followed by M. scrofulaceum (13.9%), MAC (13.5%), M. lentiflavum (1.9%), M. simiae (0.8%), M. palustre 
(0.4%) and M. abscessus (0.4%).
Country Study period Reference
Age in 
years Sample size
Sputum cultures
Most isolated 
NTM
Method of NTM 
identification
Overall 
prevalence 
of NTM 
isolation (%)
Pulmonary 
NTM 
patients 
with HIV 
coinfection 
(%)
ATS/IDSA 
applied/
numbers 
meeting 
criteria
Risk 
factors for 
pulmonary 
NTMMTBC NTM
Tanzania 2012–13 Hoza et al.33 40 7–88 372 presumptive TB cases 85 36
M. gordonae M. 
interjectum M. 
avium complex M. 
scrofulaceum
Molecular (Genotype 
CM/AS assay) 9.7 33 No
HIV 
infection 
and age
Tanzania 2011 Haraka et al.34 35
1 HIV negative 
patient with 
prior TB
NA 1 M. intracellulare Molecular (Genotype CM/AS assay) 100 100 Yes;1 Previous TB
Tanzania 2001–13 Katale et al.32 NA 472 presumptive TB cases NA 12
M. chelonae M. 
abscessus M. 
spaghni
Molecular (Sequencing of 
16S rRNA gene) 2.5 NA No NA
Uganda 2009 Asimwe  et al.30 12–18
2200 (710 
infants and 1490 
adolescents 
presumptive TB 
cases)
8 95 M. fortuitum M. szulgai M. gordonae
Molecular (Genotype 
CM/As assay) 4.3 NA No NA
Uganda 2012–13 Bainomugisa et al.31 NA
241 presumptive 
TB cases 95 14
M. avium M. 
kansasii
Molecular (Polymerase 
Chain Reaction of 16S 
rDNA using the Light 
cycler)
5.8 NA No NA
Zambia 2009–12 Mwikuma et al.25 NA
91 NTM 
suspected isolates NA 54
M. intracellulare 
M. lentiflavum. M. 
avium
Molecular (Genotype 
CM/As assay) 59.3 NA No NA
Zambia NA Kapta et al.24 ≥1 6123 presumptive TB cases enrolled 265 923 NTM not identified
Immunochromatography 
assay (Capilia TAUNS 
method)
15.1 5.8 No TB and HIV infection
Zambia 2001 Buijtels et al.26 ≥15 167 chronically ill patients 74 93
M. intracellulare 
M. lentiflavum M. 
chelonae
Molecular (Sequencing of 
16S rRNA gene) 55.6 79.0 Yes; 7
Previous 
TB HIV 
infection
Zambia 2001 Buijtels et al.10 ≥25 4 presumptive TB cases NA 4
M. lentiflavum M. 
goodie
Molecular (Sequencing of 
16S rRNA gene) 100.0 33.0 No
HIV 
infection, 
damaged 
lungs
Zambia 2011-12 Malama  et al.27 NA
100 presumptive 
TB cases 46 9
M. intracellulare 
M. abscessus M. 
chimera
Molecular (Sequencing of 
16S rRNA gene) 9.0 NA NA NA
Zambia 2002–03 Buijtels et al.6 ≥15
565 (180 
chronically ill 
patients and 385 
healthy controls)
205 93
M. intracellulare 
M. lentiflavum. M. 
avium
Molecular (Sequencing of 
16S rRNA gene) 16.5 45.6 Yes; 1
Previous 
TB HIV 
infection, 
and use of 
tap water
Table 2. Overview of studies on pulmonary non-tuberculous mycobacteria in sub-Saharan Africa. NA = Data 
not available in article.
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Figure 3 shows the distribution of NTM species causing pulmonary NTM disease in sub-Saharan Africa by 
country. The studies investigating the clinical relevance of NTM isolates varied substantially in design, participant 
characteristics and background HIV prevalence (see Table 2). They ranged from a Zambian study that evaluated 
the clinical relevance of NTM isolated from 180 chronically ill patients and 385 healthy controls and found only 
1.1% of isolates were clinically relevant6, to a Malian study in patients with primary and chronic pulmonary tuber-
culosis where 57.9% of isolated NTM were clinically relevant22.
Clinical and Radiological Signs, and Associated Morbidities. Of 3096 participants with NTM isolates, 
80.7% (2498) and 87.5% (2,709) had clinical and radiological information respectively5,6,15,16,21,22,24–26,29,34,38–40,43,45. 
Clinical characteristics for NTM subjects closely mimicked those of pulmonary tuberculosis, as summarized in 
Table 4. There were radiological abnormalities in 79.0% (2141) of 2709 subjects, while 21.0% (568) had normal 
chest radiographs. Of the 512 with prior lung disease, 87.1% (446) had a history of tuberculosis and 12.9% (66) 
had bronchiectasis. In those with concurrent conditions, 50.2% (442) of 880 were coinfected with HIV, 28.2% 
(248) reported gastrointestinal diseases and 8.6% (76) complained of body weakness. Other characteristics are 
shown on Table 4.
Discussion
We provide an overview of the epidemiology and geographical distribution of NTM species isolated from pul-
monary samples in sub-Saharan Africa. To our knowledge, this is the first comprehensive review of pulmonary 
NTM in this part of the world. Similar to reviews by other authors, our findings suggest diversity in prevalent 
NTM species, geographical variation in NTM distribution and their clinical relevance across the sub-continent48.
The global collection of NTM isolated from pulmonary samples reported by Hoefsloot et al.8 in 2008 included 
isolates from only one sub-Saharan Africa country, South Africa. The update in 2013 by Kendall et al. did not 
improve significantly on the earlier review with respect to additional African NTM isolates1. Despite the relative 
scarcity of local data, it is important to highlight that this review is the first to include NTM data for nine coun-
tries in sub Saharan Africa.
Overall, we found a predominance of MAC from pulmonary samples in countries of Western, Eastern and 
Southern Africa. M. scrofulaceum and M. kansasii were predominant in Southern Africa and the rapidly grow-
ing mycobacteria (M. abscessus, M. fortuitum and M. chelonae) in Eastern Africa. These findings are consistent 
with the predominance of MAC in the epidemiology of NTM in North America1,2,49, Europe50, Australia51 and 
East Asia14. The relative preponderance of the two members of the MAC family also varied by region with M. 
intracellulare predominating in South Africa while all MAC isolates from Mali were M. avium. However, the 
South African study had a much bigger sample size compared to the Malian study. While MAC was the most 
frequently implicated NTM in colonisation, M. kansasii was the most common in pulmonary NTM disease. The 
dominance of M. kansasii as well as the presence of M. scrofulaceum in South Africa was speculated to be linked 
to mining activities and significant urbanisation in the country, resulting in a socio-economically disadvantaged 
population7,52,53, working in the mines, frequently suffering from silicosis, while living in poor, overcrowded envi-
ronments (also see Table 2). When the South Africa pulmonary NTM data is excluded, MAC is the major cause 
of pulmonary NTM disease as reported in North America, Europe, Australia and Asia1. Because relatively few 
studies in this review applied the ATS/IDSA criteria for confirmation of pulmonary NTM disease, it is difficult 
to reach conclusions regarding the dominant NTM species causing pulmonary disease in sub-Saharan Africa.
The reason for the observed geographical variation in NTM populations across Africa is still unknown, and 
could be due to environmental factors associated with the differing geographical country locations. Unfortunately 
included studies were not designed to investigate sub-regional geographical variation and did not systematically 
collect environmental data. Ideally future studies on NTM in Africa could address this issue.
In contrast to observations from other parts of the world, especially in Europe, where M. malmoense and M. 
xenopi are well known for causing pulmonary NTM disease1,54,55, these NTM were not represented in the limited 
number of studies reviewed here. M. xenopi was rare in sub-Saharan Africa, which is not unexpected considering 
its association with hot water delivery systems that are less developed in sub-Saharan Africa compared to indus-
trialised countries2,56.
Pulmonary NTM was commonly associated with a history of previous pulmonary tuberculosis in sub-Saharan 
Africa compared to Europe and North America. This is not surprising given the high incidence of MTBC disease 
in sub-Saharan Africa57,58. Pulmonary tuberculosis is associated with significant sequelae that have not been 
adequately studied in sub-Saharan Africa. The associated structural lung damage, chronic pulmonary obstructive 
disease and infections most likely favour colonization by NTM and other pathogens59. It is also likely that the 
increasing isolation of NTM has come from investigation of patients with chronic pulmonary disease including 
those complicating previous pulmonary tuberculosis6,22. In light of this, the clinical, radiological and microbio-
logic criteria of the ATS\IDSA is important for distinguishing colonization from pulmonary NTM, particularly 
in sub-Saharan Africa that is endemic for MTBC60.
Many rarely isolated NTM were also identified in presumptive tuberculosis patients, for example M. genavense, 
M. gilvum, M. intermedium, M. poriferae, M. spaghni, M. interjectum, M. peregrinum, M. moriokaense, M. kum-
amotonense and M. kubicae. Although some of these species have also been isolated in other parts of the world 
from pulmonary samples in patients with chronic bronchitis, pulmonary tuberculosis, sub-acute pneumonia and 
healed tuberculosis61,62, it is currently unclear what role they play in the aetiology of pulmonary disease in Africa.
The HIV-driven increase in the risk of tuberculosis disease in sub-Saharan Africa has been well described and 
for NTM, MAC is a particularly well described opportunistic infection in patients with AIDS. We found almost 
half of all cases of confirmed pulmonary NTM were also HIV co-infected. This suggests the possibility of HIV 
attributable pulmonary NTM beyond the now familiar disseminated MAC disease often seen in persons with 
AIDS.
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Non-tuberculous 
mycobacteria species
Prior 2010 Biochemical 
identification methods
After 2010 Molecular 
identification methods
Previously 
associated with 
disease
M. intracellulare Y Y Y
M. avium Y Y Y
M. kansasii Y Y Y
M. chelonae Y Y Y
M. abscessus Y Y Y
M. fortuitum Y Y Y
M. scrofulaceum Y Y Y
M. lentiflavum Y Y Y
M. interjectum Y Y Y
M. peregrinum Y Y N
M. gordonae Y Y N
M. xenopi Y Y Y
M. malmoense Y Y Y
M. moriokaense Y Y N
M. kumamotonense N Y N
M. kubicae Y Y N
M. gordonae Y Y N
M. simiae Y Y Y
M. palustre Y Y Y
M. indicus pranii N Y N
M. elephantis N Y N
M. flavascens Y Y N
M. bouchedurhonense N Y N
M. chimera N Y Y
M. europaeum N Y N
M. neoaurum N Y N
M. asiaticum Y Y N
M. nonchromogenicum N Y N
M. gastri Y Y N
M. nebraskense Y Y N
M. confluentis Y Y N
M. porcinum Y Y Y
M. terrae Y Y N
M. seoulense Y Y N
M. engbackii Y Y N
M. parascrofulaceum Y Y N
M. triviale Y Y N
M. scrofulaceum Y Y Y
M. szulgai Y Y Y
M. heckeshornense Y Y N
M. poriferae Y Y N
M. spaghni Y Y N
M. goodie Y Y N
M. aurum Y Y N
M. conspicum Y Y N
M. mucogenicum Y Y N
M. rhodesia Y Y N
M. gilvum Y Y N
M. genevanse N Y N
M. intermidium N Y N
M. fortuitum 11/M. 
magaritense N Y Y
Table 3. Non–tuberculous mycobacteria species isolated from sub-Saharan Africa, 1965–2016‡. Y = isolated 
N = not isolated. ‡Data retrieved from refs5,6,8,10,16–40,43–46.
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Figure 2. The distribution of the top four non-tuberculous mycobacteria species identified from pulmonary 
samples in Mali (HIV 1.4%), Ghana (HIV prevalence 1.3), Nigeria (HIV 3.1%), Uganda (HIV 7.1%), Kenya 
(HIV 5.9%), Tanzania (HIV 4.7%), Zambia (HIV 12.9%), and Republic of South Arica (HIV 19.2%), without 
considering clinical relevance. Data compiled from refs5,6,8,10,13,15–17,19–33,35–46. HIV prevalence compiled from 
ref.47.
Figure 3. Non-tuberculous mycobacteria species causing pulmonary disease (based on ATS/ISDA criteria) 
found in respiratory specimens in sub-Saharan Africa. Data compiled from refs6,22,26,34,39,40,43.
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Persons with pulmonary NTM infection in sub-Saharan Africa are younger than observed in North America, 
Europe and Australia where increasing age (≥50 years), structural lung damage, immunosuppressive chemo-
therapy for cancer, autoimmune and rheumatoid conditions are the most frequently reported risk factors for 
this disease1,2,59,63. Given the younger age and higher burden of pulmonary tuberculosis and HIV co-infection in 
sub-Saharan Africa, it is not surprising that we found pulmonary NTM infection mostly in the 33–44 year-age 
group. As the ATS/ISDA compliant studies did not describe the clinical characteristics of individual NTM 
patients, a risk-factor analysis for NTM disease could not be conducted in the present review.
Our review has a number of limitations: we only searched for English language-articles. Given the numbers of 
Francophone countries in sub-Saharan Africa, French-language publications may have been missed. In addition, 
our assessment of the clinical relevance of isolated NTM was not as comprehensive as desired because the major-
ity of the studies did not collect the detailed clinical, radiological and microbiological data required to do this. 
We also could not report the full diversity of NTM in colonization and disease because almost 30% of all isolates 
were not fully identified to species level. Since the studies reviewed came from varied time periods during which 
laboratory procedures for ascertainment differed, we cannot exclude the possibility of laboratory procedures 
before and/or after year 2000 selecting for particular NTM species whilst inhibiting others64. For example, the 
wider usage of sensitive liquid culture media could in theory have selected for specific NTM species. Similarly, 
the increasing use of molecular methods for identification of current and historical isolates, especially for the 
MAC and rapidly growing mycobacteria groups, could underpin the changes to NTM taxonomy over time65–67. 
However, we think our results were not significantly affected because the distribution of NTM species identified 
in the periods before and after 2010 were similar. Given the heterogeneity of studies included in this review 
including laboratory methods and quality standards, some of the NTM reported here may be due to contami-
nation especially for NTM like M.flavescens that are frequent laboratory contaminants. It is possible for example 
that all seven M. flavescens are contaminants. In more than half of 26 studies that used molecular techniques to 
identify NTM, 16s rDNA sequencing was used. However, this method has a limitation in that it is not fully capa-
ble of distinguishing between all the different NTM species for example M. abscessus and M. chelonae. Therefore, 
it is possible some species have been misidentified or misclassified in these studies.
Characteristic Numbers (%)
Clinical signs n = 2, 498
Cough ≥ 2 weeks 950 (38.0%)
Chest pain 684 (27.3%)
Significant weight loss 546 (21.9%)
Fever ≥ 2 455 (18.2%)
Night sweats 211 (8.4%)
Haemoptysis 27 (1.1%)
Dyspnoea 19 (0.8%)
Previous lung disease n = 512
Bronchiectasis 66 (12.9%)
Tuberculosis 446 (87.1%)
Radiographic findings n = 2709
Abnormal, suggestive of TB 1009 (37.2%)
No pathological changes 568 (20.9%)
Tuberculosis 446 (16.5%)
Nodules 203 (7.5%)
Fibrosis 140 (5.2%)
Cavitation 127 (4.7%)
Prior focal radiological scarring 107 (4.0%)
Bronchiectasis 66 (2.4%)
Abnormal, not consistent with TB 24 (0.9%)
Milliary TB 19 (0.7%)
Concurrent conditions n = 880
HIV infection 442 (50.2%)
Gastrointestinal disease 248 (28.2%)
Weakness 76 (8.6%)
Lymph node enlargement 52 (6.0%)
Splenomegaly 21 (2.4%)
Diabetes mellitus 22 (2.5%)
Hepatomegaly 19 (2.2%)
Table 4. Clinical and radiographic characteristics for patients with pulmonary non-tuberculous mycobacteria 
infections in sub-Saharan Africa, 1965–2016 (N = 3096).
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To conclude, we have provided the first detailed review of pulmonary NTM in sub-Saharan Africa and high-
light the contribution of NTM to the aetiology of tuberculous-like pulmonary disease in the sub-continent. Our 
review also suggests that the presence of NTM as commensals in pulmonary samples may confound the diagnosis 
of pulmonary tuberculosis, especially in those with a previous history of tuberculosis and/or other chronic res-
piratory conditions.
Additional research and surveillance is required for investigation of the full contribution of NTM to pulmo-
nary disease, to describe the full repertoire of prevalent and incident NTM, and to determine the role of risk 
factors (particularly HIV/AIDS) for colonization and/or disease. Given the risk of over diagnosis of NTM in 
pulmonary samples as tuberculosis disease, resulting in repeated courses of treatment in previously treated tuber-
culosis patients, investments in, and development of, point of care diagnostics for NTM are required.
Evidence before this Study. We searched PubMEd, Embase and other databases for the terms “nontu-
berculous mycobacteria*”, “pulmonary*”, “africa south of the sahara*”, “lung”, and “human”. We searched for 
English-language articles published up to Oct 1, 2016 and reviewed all eligible articles and their reference lists. 
Earlier reviews only included NTM isolates, subject level data from just one sub-Saharan Africa country and did 
not investigate the clinical relevance of isolated NTM.
Added Value of this Study. This is the first review to utilise all available data to provide a detailed picture 
of the clinical and molecular epidemiology of NTM isolated from pulmonary samples in sub-Saharan Africa. As 
a result, we find there is a substantial burden of pulmonary NTM in the sub-continent. With seven out of every 
100 presumptive tuberculosis cases either colonised or diagnosed with confirmed pulmonary NTM, the likeli-
hood of pulmonary tuberculosis over diagnosis especially in those with previous history of tuberculosis requires 
further investigation. In addition, we highlight the knowledge gap resulting from incomplete identification of 
NTM species.
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